Alicia C. Olivo - Sep 30, 2023 Form 4 Insider Report for NEOGENOMICS INC (NEO)

Role
General Counsel
Signature
/s/ Alicia C. Olivo
Stock symbol
NEO
Transactions as of
Sep 30, 2023
Transactions value $
$0
Form type
4
Date filed
10/3/2023, 05:50 PM
Previous filing
Sep 5, 2023
Next filing
Nov 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NEO Common Stock Tax liability $0 -14 -0.04% $0.00 39.5K Sep 30, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NEO Stock Option (Right to Buy) 1.05K Sep 30, 2023 Common Stock 1.05K $19.12 Direct F3
holding NEO Stock Option (Right to Buy) 1.02K Sep 30, 2023 Common Stock 1.02K $27.34 Direct F4
holding NEO Stock Option (Right to Buy) 516 Sep 30, 2023 Common Stock 516 $48.99 Direct F5
holding NEO Stock Option (Right to Buy) 1.12K Sep 30, 2023 Common Stock 1.12K $46.10 Direct F6
holding NEO Stock Option (Right to Buy) 22.2K Sep 30, 2023 Common Stock 22.2K $9.45 Direct F7
holding NEO Stock Option (Right to Buy) 55.3K Sep 30, 2023 Common Stock 55.3K $10.05 Direct F8
holding NEO Stock Option (Right to Buy) 36.5K Sep 30, 2023 Common Stock 36.5K $19.65 Direct F9
holding NEO Restricted Stock Unit 19.5K Sep 30, 2023 Common Stock 19.5K $0.00 Direct F10, F11
holding NEO Performance Stock Unit 19.5K Sep 30, 2023 Common Stock 19.5K $0.00 Direct F11, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the September 30, 2023 vesting of restricted stock.
F2 This balance includes 101 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3.
F3 On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vested ratably over the first four anniversary dates of the grant date.
F4 On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F5 On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F6 On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F7 On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F8 On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F9 On May 11, 2023, Ms. Olivo was granted 36,508 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F10 On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F11 Once vested, the shares of common stock are not subject to expiration.
F12 On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.